durvalumab - Medxy AI

Starting Durvalumab with Chemoradiotherapy in Unresectable Stage III NSCLC Did Not Improve Outcomes: PACIFIC-2 Recalibrates the Timing of Immunotherapy

By MedXY 12/10/2025

The phase III PACIFIC-2 trial found that giving durvalumab from the start of definitive concurrent chemoradiotherapy failed to improve progression-free or overall survival versus placebo; consolidation durvalumab after chemoradiotherapy remains the standard of care.

news Oncology Respiratory

Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)

By MedXY 12/01/2025

NEJ045A shows durvalumab plus carboplatin–etoposide is feasible in ES‑SCLC patients with PS2–3, with induction completion rates above thresholds and a 1‑year survival of 43.4% overall, supporting cautious use of chemo‑immunotherapy in selected frail patients.

news Oncology Urology

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

By MedXY 11/11/2025

One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety profile.

news Oncology Respiratory

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

By MedXY 10/29/2025

A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.

Gastroenterology news Oncology

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY 10/29/2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Clinical Updates news Oncology

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma

By MedXY 09/20/2025

The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.